Compare Fidelity National Information Servcs Inc (FIS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Novo Nordisk A/S — how do they compare? Fidelity National Information Servcs Inc trades at $41.65 (market cap $21.24B), while Novo Nordisk A/S trades at $51.56 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 10.5× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4.09%). Which is the better fit depends on your goals.
| FIS | NVO | |
|---|---|---|
Market Cap | $21.24B | $222.24B |
Sector | Technology | Health |
52-Week High | $81.94 | $71.70 |
52-Week Low | $37.72 | $35.29 |
Enterprise Value | $41.63B | $241.20B |
Dividend Yield | 4.09% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS (Fidelity National Information Services) trades at $40.58, down 3.22% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $1.36 versus $1.29, and analyst consensus remains strong with 21 Buy ratings and a $52.57 price target. Recent business developments include winning Frankfurt International Bank as a cloud banking client and receiving industry awards for AI-embedded risk technology.
The outlook presents a value opportunity with a low P/E of 7.97 and improving profit margins, though execution risks persist from the Worldpay divestiture and net cash flow volatility. Upside potential exists if the company capitalizes on its $42 billion market opportunity in digital payments and maintains its recent earnings momentum.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
